Compound News and Research

RSS

Researchers find link between acrolein and multiple sclerosis

Researchers have found evidence that an environmental pollutant may play an important role in causing multiple sclerosis and that a hypertension drug might be used to treat the disease.

24 Nov 2010

Preclinical trial shows Chimerix’s CMX001 inhibits HSV replication

Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced that data demonstrating preclinical efficacy of Chimerix's lead antiviral compound CMX001 against herpes simplex virus (HSV) as well as its ability to penetrate the blood-brain barrier was published in the November 15, 2010 issue of The Journal of Infectious Diseases.

23 Nov 2010

Apricus files protocol of PrevOnco Phase 3 clinical trial for FDA SPA program

Apricus Biosciences, Inc., today announced that it has filed the protocol for a proposed Phase 3 clinical trial of PrevOnco, its proprietary treatment for hepatocellular carcinoma (liver cancer), with the U.S. Food and Drug Administration (FDA).

23 Nov 2010

Omthera reaches agreement with FDA on SPA for Epanova Phase III trial in patients with very high triglycerides

Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, today announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the design of its planned Phase III registration clinical trial of Epanova™, the Company's lead compound for the treatment of patients with very high triglycerides. Epanova is an Omega 3 fatty acid containing a novel formulation of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).

22 Nov 2010

Profil Institute expands capabilities to detect cardiac safety signals in diabetes and obesity clinical trials

Profil™ Institute for Clinical Research, Inc., a company specializing in early phase clinical trials for diabetes and obesity, announced today the expansion of its capabilities for cardiac safety and cardiovascular efficacy studies in the company's early phase diabetes and obesity clinical trials.

22 Nov 2010

$S*BIO begins SB1317 Phase 1 clinical trial in patients with advanced/refractory hematologic malignancies$

S*BIO begins SB1317 Phase 1 clinical trial in patients with advanced/refractory hematologic malignancies

S*BIO Pte Ltd today announced that a fourth novel, potential best-in-class compound discovered and developed by S*BIO has entered a Phase 1 clinical trial. The initiation of the study for S*BIO's oral multi-kinase inhibitor, SB1317 or TG02, in patients with advanced/refractory hematologic malignancies has triggered a payment from S*BIO's development and commercialization partner for the program, Tragara Pharmaceuticals.

22 Nov 2010

Stealth Peptides introduces Bendavia clinical candidate at AHA Scientific Sessions

Stealth Peptides, a privately held biopharmaceutical company developing innovative mitochondrial therapies for diseases with significant unmet medical needs, introduced its lead clinical candidate, Bendavia, a novel compound that targets the mitochondrion, at the 2010 American Heart Association's (AHA) Scientific Sessions, Resuscitation Science Symposium.

22 Nov 2010

Medco shares 10-year strategic financial plan

Medco Health Solutions, Inc. today presented the results of a recently completed strategic financial plan that forecasts a decade of substantial growth through 2020.

20 Nov 2010

Pfizer's Phase 3 AXIS 1032 trial for metastatic renal cell carcinoma meets primary endpoint

Pfizer Inc. announced today that the Phase 3 AXIS 1032 trial (A4061032), studying the investigational compound axitinib in previously treated patients with metastatic renal cell carcinoma (mRCC), has met its primary endpoint, demonstrating that axitinib significantly extended progression-free survival when compared to sorafenib, in the study population.

20 Nov 2010

Discovery could provide new approaches to treat metabolic disorders

Scientists from the Florida campus of The Scripps Research Institute have identified a novel synthetic activator of a pair of proteins that belong to a protein family playing key roles in human metabolism and immune function. The discovery could provide new and potentially more effective therapeutic approaches to diseases ranging from diabetes to osteoporosis.

20 Nov 2010

Stromedix obtains license from UCSF for integrin αvβ5 antibody

Stromedix, Inc., a biotechnology company focused on innovative therapies for fibrosis and organ failure, announced today that it has exclusively licensed the rights to a monoclonal antibody to integrin αvβ5 from the University of California. This compound is the second Stromedix pipeline asset to be sourced from the laboratory of Dean Sheppard, M.D., at University of California, San Francisco.

19 Nov 2010

ImmunoGen presents positive data on IMGN388 anticancer compound at EORTC-NCI-AACR Symposium

ImmunoGen, Inc., a biotechnology company that develops antibody-based anticancer products using its Targeted Antibody Payload (TAP) technology, today announced the presentation of encouraging clinical data for the Company's IMGN388 anticancer compound at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place in Berlin, Germany.

19 Nov 2010

Glutaminase inhibitor: New potential target for brain tumors

Scientists at Johns Hopkins have identified a compound that could be used to starve cancers of their sugar-based building blocks. The compound, called a glutaminase inhibitor, has been tested on laboratory cultured, sugar-hungry brain cancer cells and, the scientists say, may have the potential to be used for many types of primary brain tumors.

19 Nov 2010

Scientists solve receptor structure that responds to neurotransmitter dopamine

A team led by scientists at The Scripps Research Institute has solved the structure of one of the receptors that responds to the neurotransmitter dopamine. Although dopamine transmission is essential to normal brain functioning, the biological assembly of the molecules involved in this crucial neuronal interplay had not been known until now.

19 Nov 2010

Advanced Life Sciences submits application to FDA for ALS-886 to treat ARDS

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that the Company has applied to the U.S. Food and Drug Administration for orphan drug designation for ALS-886, a novel therapy to reduce and prevent tissue damage, for the treatment of Acute Respiratory Distress Syndrome (ARDS).

19 Nov 2010

Ipsen initiates patient treatment in phase III OBI-1 study for acquired hemophilia A

Ipsen announced today that its partner Inspiration Biopharmaceuticals, Inc. has initiated treatment of patients in the first of two phase III pivotal clinical studies of OBI-1, an intravenous recombinant porcine factor VIII (FVIII) product, for the treatment of acquired hemophilia A, a rare, though potentially life-threatening bleeding disorder.

19 Nov 2010

New findings show promising treatment for MS

Successfully treating and reversing the effects of multiple sclerosis, or MS, may one day be possible using a drug originally developed to treat chronic pain, according to Distinguished Professor Linda Watkins of the University of Colorado at Boulder.

19 Nov 2010

Aeterna presents data on AEZS-108 Phase 2 study for endometrial cancer at EORTC-NCI-AACR Symposium

Aeterna Zentaris Inc., earlier today, presented Phase 2 positive efficacy and safety data for its compound, AEZS-108, in advanced endometrial cancer.

18 Nov 2010

Neural differences may help explain prevalence of mental disorders in boys

Many mental health disorders, such as autism and schizophrenia, produce changes in social behavior or interactions. The frequency and/or severity of these disorders is substantially greater in boys than girls, but the biological basis for this difference between the two sexes is unknown.

18 Nov 2010

Anti-cancer drug smuggled using a nanocarrier past protective blood-brain barrier into brain tumours

Scientists in Germany have developed a way of smuggling an anti-cancer drug past the protective blood-brain barrier and into brain tumours and metastases using a nanocarrier - a tiny capsule specially designed to pass through cell membranes and deliver its anti-cancer drug to the cancer cell.

18 Nov 2010

Compound News and Research

Researchers find link between acrolein and multiple sclerosis

Preclinical trial shows Chimerix’s CMX001 inhibits HSV replication

Apricus files protocol of PrevOnco Phase 3 clinical trial for FDA SPA program

Omthera reaches agreement with FDA on SPA for Epanova Phase III trial in patients with very high triglycerides

Profil Institute expands capabilities to detect cardiac safety signals in diabetes and obesity clinical trials

S*BIO begins SB1317 Phase 1 clinical trial in patients with advanced/refractory hematologic malignancies

Stealth Peptides introduces Bendavia clinical candidate at AHA Scientific Sessions

Medco shares 10-year strategic financial plan

Pfizer's Phase 3 AXIS 1032 trial for metastatic renal cell carcinoma meets primary endpoint

Discovery could provide new approaches to treat metabolic disorders

Stromedix obtains license from UCSF for integrin αvβ5 antibody

ImmunoGen presents positive data on IMGN388 anticancer compound at EORTC-NCI-AACR Symposium

Glutaminase inhibitor: New potential target for brain tumors

Scientists solve receptor structure that responds to neurotransmitter dopamine

Advanced Life Sciences submits application to FDA for ALS-886 to treat ARDS

Ipsen initiates patient treatment in phase III OBI-1 study for acquired hemophilia A

New findings show promising treatment for MS

Aeterna presents data on AEZS-108 Phase 2 study for endometrial cancer at EORTC-NCI-AACR Symposium

Neural differences may help explain prevalence of mental disorders in boys

Anti-cancer drug smuggled using a nanocarrier past protective blood-brain barrier into brain tumours

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News